Pharmacokinetics of Telavancin in Normal and Obese Subjects

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to characterize plasma and urinary concentrations of telavancin following intravenous administration of a single dose of telavancin in healthy subjects who are normal weight, overweight, and obese.

Key facts

Study ID

NCT02753855

Run by

University of Illinois at Chicago

People needed

32

Starts

2016-04-01

Expected to finish

2016-10-01

Last updated by the study team

2016-11-02

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult subjects, 18 to 50 years
• Nonsmokers within the last 1 year
• Weight > 110 lbs

You may not qualify if…

• History of significant hypersensitivity reaction or intolerance to telavancin
• Aspartate or alanine aminotransferase > 1.5 times the upper limit of normal
• Estimated creatinine clearance <60 mL/minute and serum creatinine >1.5 mg/dL
• Female subjects who are pregnant or breast feeding
• History of alcohol or substance abuse or dependence within the last 1 year
• Use of prescription or nonprescription drugs (unless hormonal contraceptives) within 7 to 14 days prior to telavancin administration
• Participation in a clinical trials within last 30 days
• Donated blood (>500 mL) within the last 56 days

Where it is running

• University of Illinois at Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.